108 related articles for article (PubMed ID: 37248032)
1. Evaluation of drug cost savings related to clinical trials from the perspective of a university hospital.
Perrier Q; Minoves M; Cerana S; Reymond F; Ducki C; Decaens T; Lehmann A; Bedouch P
Eur J Hosp Pharm; 2023 May; ():. PubMed ID: 37248032
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical cost savings from the treatment of oncology patients in clinical trials.
Gómez Mediavilla B; Lanza León P; Martínez Callejo V; Cantarero Prieto D; Lanza Postigo M; Salcedo Lambea M; Blanco Mesonero Y; Ochagavia Sufrategui M; Durán I; Sarabia Cobo CM
Biomed J; 2024 Apr; ():100742. PubMed ID: 38679197
[TBL] [Abstract][Full Text] [Related]
3. The role of clinical trials in the sustainability of the Italian national health service cancer drug expenditure.
Gasperoni L; Cafaro A; Ferretti E; Di Iorio V; Nanni O; Masini C
Eur J Hosp Pharm; 2023 Mar; 30(2):96-100. PubMed ID: 35577545
[TBL] [Abstract][Full Text] [Related]
4. Drug cost savings in phase III hematological oncology clinical trials in a university hospital.
Herledan C; Ranchon F; Schwiertz V; Baudouin A; Karlin L; Ghesquières H; Salles G; Rioufol C
Hematol Oncol; 2020 Oct; 38(4):576-583. PubMed ID: 32469095
[TBL] [Abstract][Full Text] [Related]
5. Retrospective pharmaceutical financial benefits and cost avoidance analysis of clinical trial participation in the Australian haematology setting.
Truong K; Kwan YL; Nigro L; Huseincehajic A; Trotman J
Intern Med J; 2019 Sep; 49(9):1092-1098. PubMed ID: 30907047
[TBL] [Abstract][Full Text] [Related]
6. Drug cost avoidance in clinical trials of breast cancer.
Mañes-Sevilla M; Romero-Jiménez R; Herranz-Alonso A; Sánchez-Fresneda M; Gonzalez-Haba E; Collado-Borrel R; Benedi-González J; Sanjurjo-Sáez M
J Oncol Pharm Pract; 2019 Jul; 25(5):1099-1104. PubMed ID: 29792122
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System.
Torres A; Soriano A; Rivolo S; Remak E; Peral C; Kantecki M; Ansari W; Charbonneau C; Hammond J; Grau S; Wilcox M
Clinicoecon Outcomes Res; 2022; 14():149-161. PubMed ID: 35330907
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective.
Luporsi E; Mahi L; Morre C; Wernli J; de Pouvourville G; Bugat R
J Med Econ; 2012; 15(2):225-32. PubMed ID: 22077267
[TBL] [Abstract][Full Text] [Related]
9. Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants.
Grau S; Solano C; García-Vidal C; Jarque I; Barrueta JA; Peral C; Rodríguez I; Rubio-Rodríguez D; Rubio-Terrés C
J Health Econ Outcomes Res; 2016; 3(2):153-161. PubMed ID: 35619591
[No Abstract] [Full Text] [Related]
10. Clinical trials and drug cost savings for Italian health service.
D'Ambrosio F; De Feo G; Botti G; Capasso A; Pignata S; Maiolino P; Triassi M; Nardone A; Perrone F; Piezzo M; Grimaldi AM; Palazzo I; De Stasio I; D'Aniello R; Morabito A; Pascarella G
BMC Health Serv Res; 2020 Nov; 20(1):1089. PubMed ID: 33243262
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials: considerations for researchers and hospital administrators.
Uecke O; Reszka R; Linke J; Steul M; Posselt T
Health Care Manage Rev; 2008; 33(2):103-12. PubMed ID: 18360161
[TBL] [Abstract][Full Text] [Related]
12. Drug Cost Avoidance in Prostate Cancer Clinical Trials.
Calvin-Lamas M; Portela-Pereira P; Rabuñal-Alvarez MT; Martinez-Breijo S; Martín-Herranz MI; Gómez-Veiga F
Actas Urol Esp; 2015 Nov; 39(9):553-7. PubMed ID: 26071987
[TBL] [Abstract][Full Text] [Related]
13. Economic outcomes associated with an investigational drug service within a Veterans Affairs health care system.
Brown JN; Tillman F; Jacob S; Britnell SR
Contemp Clin Trials Commun; 2019 Jun; 14():100354. PubMed ID: 31011657
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of fixed and variable hospital costs due to Clostridium difficile infection: institutional incentives and directions for future research.
Ryan P; Skally M; Duffy F; Farrelly M; Gaughan L; Flood P; McFadden E; Fitzpatrick F
J Hosp Infect; 2017 Apr; 95(4):415-420. PubMed ID: 28320542
[TBL] [Abstract][Full Text] [Related]
15. Treatment costs associated with interventional cancer clinical trials conducted at a single UK institution over 2 years (2009-2010).
Liniker E; Harrison M; Weaver JM; Agrawal N; Chhabra A; Kingshott V; Bailey S; Eisen TG; Corrie PG
Br J Cancer; 2013 Oct; 109(8):2051-7. PubMed ID: 24064969
[TBL] [Abstract][Full Text] [Related]
16. Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease.
Severs M; Mangen MJ; van der Valk ME; Fidder HH; Dijkstra G; van der Have M; van Bodegraven AA; de Jong DJ; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; van de Meeberg PC; Mahmmod N; Ponsioen CY; Vermeijden JR; van der Meulen-de Jong AE; Pierik M; Siersema PD; Oldenburg B;
J Crohns Colitis; 2017 Mar; 11(3):342-352. PubMed ID: 27647859
[TBL] [Abstract][Full Text] [Related]
17. An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.
Tran-Duy A; Ghiti Moghadam M; Oude Voshaar MAH; Vonkeman HE; Boonen A; Clarke P; McColl G; Ten Klooster PM; Zijlstra TR; Lems WF; Riyazi N; Griep EN; Hazes JMW; Landewé R; Bernelot Moens HJ; van Riel PLCM; van de Laar MAFJ; Jansen TL;
Arthritis Rheumatol; 2018 Oct; 70(10):1557-1564. PubMed ID: 29745059
[TBL] [Abstract][Full Text] [Related]
18. Costs and savings of investigational drug services.
McDonagh MS; Miller SA; Naden E
Am J Health Syst Pharm; 2000 Jan; 57(1):40-3. PubMed ID: 10630555
[TBL] [Abstract][Full Text] [Related]
19. Managing prices for hospital pharmaceuticals: a successful strategy for New Zealand?
Tordoff JM; Norris PT; Reith DM
Value Health; 2005; 8(3):201-8. PubMed ID: 15877592
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
